Lisa Harding, MD, says ECT, ketamine, TMS, and VNS can work, but evidence on what comes after acute response remains thin.
|Videos|November 25, 2020
The Vulnerability and Resilience of Refugees During the Pandemic
Assisting and empowering refugees is important now more than ever.
Advertisement
Andrea Mendiola, MD, and Lilanthi Balasuriya, MD, MMS, discuss and present ideas from their article,
Dr Mendiola is a Fellow, Connecticut Mental Health Center Hispanic Clinic, and Dr Balasuriya is a Fourth Year Resident, Department of Psychiatry, Yale University School of Medicine, New Haven, CT.
Advertisement
Related to this article
Why D2 blockade alone falls short in schizophrenia, and what neurotransmitter, genetic and neuroimaging research means for treatment-resistant patients.
Discover expanded psychiatry coverage with new podcasts, interactive digital issues, and event reporting—we are your always-on media hub delivering fresh insights year-round.
GLP-1 drugs enter psychiatry, curbing antipsychotic weight gain while raising new questions about addiction, mood, eating disorders, and culture.
Miss Golden Corner 2026 discusses the South Carolina campus naloxone law she helped start and her push to reduce addiction stigma in rural communities.
Explore the urgent legal, ethical, and clinical challenges in emergency psychiatry, share cases and tips, and contribute to Psychiatric Times’ November series.
A Delphi panel recommends screening for eating disorders before GLP-1 receptor agonist initiation.
Alkermes launches a phase 2 trial of oral orexin-2 agonist ALKS 7290 to boost antidepressant response in major depressive disorder, assessing safety and symptom relief.
Advertisement
Advertisement
Trending on Psychiatric Times
1
The Ozempic Dilemma: Promises and Pitfalls in Psychiatry
2
Schizophrenia: A Telltale of the Brain’s Complexity
3
Podcast: Interventional Psychiatry and the Challenge of Difficult-to-Treat Depression
4
Talking With Titans: Sheldon Preskorn, MD, on the Evolution of Psychopharmacology
5